|
1
|
Sharma SV, Haber DA and Settleman J: Cell
line-based platforms to evaluate the therapeutic efficacy of
candidate anticancer agents. Nat Rev Cancer. 10:241–253. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shamir ER and Ewald AJ: Three-dimensional
organotypic culture: Experimental models of mammalian biology and
disease. Nat Rev Mol Cell Biol. 15:647–664. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arrowsmith J and Miller P: Trial watch:
Phase II and phase III attrition rates 2011–2012. Nat Rev Drug
Discov. 12:5692013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arrowsmith J: Trial watch: Phase II
failures: 2008–2010. Nat Rev Drug Discov. 10:328–329. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
DiMasi JA, Reichert JM, Feldman L and
Malins A: Clinical approval success rates for investigational
cancer drugs. Clin Pharmacol Ther. 94:329–335. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tentler JJ, Tan AC, Weekes CD, Jimeno A,
Leong S, Pitts TM, Arcaroli JJ, Messersmith WA and Eckhardt SG:
Patient-derived tumour xenografts as models for oncology drug
development. Nat Rev Clin Oncol. 9:338–350. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Siolas D and Hannon GJ: Patient-derived
tumor xenografts: Transforming clinical samples into mouse models.
Cancer Res. 73:5315–5319. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rosfjord E, Lucas J, Li G and Gerber HP:
Advances in patient-derived tumor xenografts: From target
identification to predicting clinical response rates in oncology.
Biochem Pharmacol. 91:135–143. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hidalgo M, Amant F, Biankin AV, Budinská
E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo
GM, et al: Patient-derived xenograft models: An emerging platform
for translational cancer research. Cancer Discov. 4:998–1013. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao H, Korn JM, Ferretti S, Monahan JE,
Wang Y, Singh M, Zhang C, Schnell C, Yang G, Zhang Y, et al:
High-throughput screening using patient-derived tumor xenografts to
predict clinical trial drug response. Nat Med. 21:1318–1325. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maru Y and Hippo Y: Current status of
patient-derived ovarian cancer models. Cells. 8:5052019. View Article : Google Scholar
|
|
12
|
Weeber F, Ooft SN, Dijkstra KK and Voest
EE: Tumor organoids as a pre-clinical cancer model for drug
discovery. Cell Chem Biol. 24:1092–1100. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Crespo M, Vilar E, Tsai SY, Chang K, Amin
S, Srinivasan T, Zhang T, Pipalia NH, Chen HJ, Witherspoon M, et
al: Colonic organoids derived from human induced pluripotent stem
cells for modeling colorectal cancer and drug testing. Nat Med.
23:878–884. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sato T, Stange DE, Ferrante M, Vries RG,
Van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Gorp J,
Siersema PD, et al: Long-term expansion of epithelial organoids
from human colon, adenoma, adenocarcinoma, and Barrett's
epithelium. Gastroenterology. 141:1762–1772. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
van de Wetering M, Francies HE, Francis
JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J,
Taylor-Weiner A, Kester L, et al: Prospective derivation of a
living organoid biobank of colorectal cancer patients. Cell.
161:933–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Boj SF, Hwang CI, Baker LA, Chio II, Engle
DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, et al:
Organoid models of human and mouse ductal pancreatic cancer. Cell.
160:324–338. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao D, Vela I, Sboner A, Iaquinta PJ,
Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora
VK, et al: Organoid cultures derived from patients with advanced
prostate cancer. Cell. 159:176–187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Girda E, Huang EC, Leiserowitz GS and
Smith LH: The use of endometrial cancer patient-derived organoid
culture for drug sensitivity testing is feasible. Int J Gynecol
Cancer. 27:1701–1707. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Broutier L, Mastrogiovanni G, Verstegen
MM, Francies HE, Gavarró LM, Bradshaw CR, Allen GE, Arnes-Benito R,
Sidorova O, Gaspersz MP, et al: Human primary liver cancer-derived
organoid cultures for disease modeling and drug screening. Nat Med.
23:1424–1435. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pauli C, Hopkins BD, Prandi D, Shaw R,
Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, et al:
Personalized in vitro and in vivo cancer models to guide precision
medicine. Cancer Discov. 7:462–477. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kondo J, Endo H, Okuyama H, Ishikawa O,
Iishi H, Tsujii M, Ohue M and Inoue M: Retaining cell-cell contact
enables preparation and culture of spheroids composed of pure
primary cancer cells from colorectal cancer. Proc Natl Acad Sci
USA. 108:6235–6240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshida T, Okuyama H, Endo H and Inoue M:
Spheroid cultures of primary urothelial cancer cells: Cancer
tissue-originated spheroid (CTOS) method. Methods Mol Biol.
1655:145–153. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meijer TG, Naipal KA, Jager A and van Gent
DC: Ex vivo tumor culture systems for functional drug testing and
therapy response prediction. Future Sci OA. 3:FSO1902017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Inoue A, Deem AK, Kopetz S, Heffernan TP,
Draetta GF and Carugo A: Current and future horizons of
patient-derived xenograft models in colorectal cancer translational
research. Cancers (Basel). 11:13212019. View Article : Google Scholar
|
|
25
|
Hum NR, Sebastian A, Gilmore SF, He W,
Martin KA, Hinckley A, Dubbin KR, Moya ML, Wheeler EK, Coleman MA,
et al: Comparative molecular analysis of cancer behavior cultured
in vitro, in vivo, and ex vivo. Cancers (Basel). 12:6902020.
View Article : Google Scholar
|
|
26
|
Tamura H, Higa A, Hoshi H, Hiyama G,
Takahashi N, Ryufuku M, Morisawa G, Yanagisawa Y, Ito E, Imai JI,
et al: Evaluation of anticancer agents using patient-derived tumor
organoids characteristically similar to source tissues. Oncol Rep.
40:635–646. 2018.PubMed/NCBI
|
|
27
|
Takahashi N, Hoshi H, Higa A, Hiyama G,
Tamura H, Ogawa M, Takagi K, Goda K, Okabe N, Muto S, et al: An in
vitro system for evaluating molecular targeted drugs using lung
patient-derived tumor organoids. Cells. 8:4812019. View Article : Google Scholar
|
|
28
|
Pan C, Liu H, Robins E, Song W, Liu D, Li
Z and Zheng L: Next-generation immuno-oncology agents: Current
momentum shifts in cancer immunotherapy. J Hematol Oncol.
13:292020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hegde PS and Chen DS: Top 10 challenges in
cancer immunotherapy. Immunity. 52:17–35. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Farkona S, Diamandis EP and Blasutig IM:
Cancer immunotherapy: The beginning of the end of cancer? BMC Med.
14:732016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Andrews MC and Wargo JA: Immunotherapy
resistance: The answers lie ahead - not in front - of us. J
Immunother Cancer. 5:102017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu H, Lyu X, Yi M, Zhao W, Song Y and Wu
K: Organoid technology and applications in cancer research. J
Hematol Oncol. 11:1162018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cerignoli F, Abassi YA, Lamarche BJ,
Guenther G, Santa Ana D, Guimet D, Zhang W, Zhang J and Xi B: In
vitro immunotherapy potency assays using real-time cell analysis.
PLoS One. 13:e01934982018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ito M, Hiramatsu H, Kobayashi K, Suzue K,
Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, et
al: NOD/SCID/gamma(c)(null) mouse: An excellent recipient mouse
model for engraftment of human cells. Blood. 100:3175–3182. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang JH, Chung TD and Oldenburg KR: A
simple statistical parameter for use in evaluation and validation
of high throughput screening assays. J Biomol Screen. 4:67–73.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shah R and Lester JF: Tyrosine Kinase
Inhibitors for the treatment of EGFR mutation-positive
non-small-cell lung cancer: A clash of the generations. Clin Lung
Cancer. 21:e216–e228. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Salih HR, Antropius H, Gieseke F, Lutz SZ,
Kanz L, Rammensee HG and Steinle A: Functional expression and
release of ligands for the activating immunoreceptor NKG2D in
leukemia. Blood. 102:1389–1396. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Palechor-Ceron N, Krawczyk E, Dakic A,
Simic V, Yuan H, Blancato J, Wang W, Hubbard F, Zheng YL, Dan H, et
al: Conditional reprogramming for patient-derived cancer models and
next-generation living biobanks. Cells. 8:13272019. View Article : Google Scholar
|
|
39
|
Du Y, Li X, Niu Q, Mo X, Qui M, Ma T, Kuo
CJ and Fu H: Development of a miniaturized 3D organoid culture
platform for ultra-high-throughput screening. J Mol Cell Biol.
12:630–643. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cassidy JW, Caldas C and Bruna A:
Maintaining tumor heterogeneity in patient-derived tumor
xenografts. Cancer Res. 75:2963–2968. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shultz LD, Brehm MA, Garcia-Martinez JV
and Greiner DL: Humanized mice for immune system investigation:
Progress, promise and challenges. Nat Rev Immunol. 12:786–798.
2012. View Article : Google Scholar : PubMed/NCBI
|
